Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ElsaLys Biotech SA

http://www.elsalysbiotech.com/

Latest From ElsaLys Biotech SA

AbbVie U-Turns On Dong-A’s MerTK Program After Development Delays

After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.

South Korea Deals

Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology

Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK

Deals Business Strategies

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline

Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Mediolanum Farmaceutici Spa
UsernamePublicRestriction

Register